Cathie's Ark LogoCathie's Ark
Trading Floor Community IconFrom the Trading Floor:
Syros Pharmaceuticals Inc. Logo

ARKK Holdings of Syros Pharmaceuticals (SYRS) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
June 8, 2021SELL913ARKK
June 7, 2021SELL50000.0001%ARKK
June 4, 2021SELL100000.0003%ARKK
May 27, 2021SELL800000.0022%ARKK
May 26, 2021SELL35749080.0905%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKG$6.30
⚖️Weighting🧢Market Cap
0%$389.71m
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
5422.22
🏋️‍♀️Weight Rank Across All Funds🐻Short Percent
26714.71
🌏Country
🇺🇸United States
Description
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
Website
syros.com

Research Notes and Commentary for SYRS

No Research Notes Found for SYRS